

Cancer Prevention and Control CIRB Meeting Agenda

January 23, 2025

I. Initial Review

NRG-CC015, Harnessing E-Mindfulness Approaches for Living-After Breast Cancer---HEAL-ABC (Version Date 11/26/24)

II. Initial ReReview

CSRN1, The Vanguard Study: Testing a New Way to Screen for Cancer (Version Date 12/22/24)

III. Amendment Review Prior to Activation

EAQ223, The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials (Version Date 12/10/24)

IV. Continuing Review

MDA20-02-01, Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A randomized, Phase IIb, Window of Opportunity Presurgical Trial. (Version Date 08/26/24)



V. Continuing Review

NRG-CC008, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] (Version Date 05/31/24)

VI. Continuing Review

NWU20-02-01, Surgical Window of Opportunity Study of Megestrol Acetate Compared with Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia (Version Date 12/11/23)

VII. Continuing Review

NWU20-02-02, A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 By Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer (Version Date 12/21/23)

VIII. Continuing Review

UMI22-09-01, Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer (Version Date 04/19/24)



IX. Continuing Review

UWI20-00-01, A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Participants with Triple Negative Breast Cancer (Version Date 04/17/24)